Search clinical trials for: HLX14

Total 132 results

Shanghai Henlius Biotech

Unknown

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Withdrawn

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Hepatocellular Carcinoma (HCC)

China
Shanghai Henlius Biotech

Not yet recruiting

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Recruiting

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Shanghai Zhongshan Hospital
Shanghai Henlius Biotech

Not yet recruiting

Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Shandong University

Recruiting

Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

Cervical Cancer

China
Zhejiang Cancer Hospital

Recruiting

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Extensive Stage Lung Small Cell Cancer

China
Shanghai Henlius Biotech

Recruiting

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Shanghai Henlius Biotech

Active, not recruiting

A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Shanghai Henlius Biotech

Recruiting

Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma by AJCC V8 Stage

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor

China
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Postmenopausal

China
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
Shanghai Henlius Biotech

Terminated

Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects

Healthy Male Volunteers

China
Shanghai Henlius Biotech

Completed

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Healthy Male Volunteers

China
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Henan Cancer Hospital

Not yet recruiting

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Metastatic Colon Cancer
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

ESCC or Esophageal Adenosquamous Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

HER2-positive Gastric Cancer
Shanghai Henlius Biotech

Active, not recruiting

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Limited Stage Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Shanghai Henlius Biotech

Withdrawn

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Cervical Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

Cervical Cancer

China
Shanghai Henlius Biotech

Completed

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
Shanghai Henlius Biotech

Active, not recruiting

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

United States, Singapore, Spain, Germany, Slovakia, China, Hungary, Australia, Bulgaria, Poland, Latvia, Czechia, France, Italy, Serbia
Ruijin Hospital

Not yet recruiting

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer (NeoCHIC)

Colon Cancer

China
Shanghai Henlius Biotech

Recruiting

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Nantes University Hospital
Fondation de France; Nantes Université

Recruiting

DEprescribing: Perceptions of PAtients Living With Advanced Cancer (DEPAL)

Deprescribing | Palliative Care | Oncology

France
Henlix, Inc

Unknown

Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients

Hepatitis B, Chronic

Taiwan
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer

China
RenJi Hospital

Recruiting

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

Serplulimab,Gastric Cancer, Adjuvant Therapy

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Malignant Ascites
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Squamous Non Small Cell Lung Cancer

China, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
Mayo Clinic

Recruiting

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

AL Amyloidosis

United States
Shanghai Henlius Biotech

Not yet recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Small-cell Lung Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

China, Georgia, Poland, Russian Federation, Turkey, Ukraine
Shanghai Henlius Biotech

Recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Healthy Male Volunteers

China
Shanghai Henlius Biotech

Suspended

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC

Colorectal Cancer Metastatic

China
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

Breast Cancer

United States
Shanghai Henlius Biotech

Active, not recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Multiple Myeloma

China
Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China

3

Subscribe